Prader-willi syndrome (PWS) is a genetic disorder that causes alteration in eating, behaviour and mood, intellectual development, and physical growth. The disease occurs due to mutation in chromosome 15, which regulate the gene expression. The inability to control eating is one of the main symptoms of PWS. The physical symptoms of PWS generally prompts the occurrence of the disease in the new-born. There are few criteria that defines PWS, including extremely weak muscles, feeding difficulties, uncontrollable overeating, rapid weight gain, and reduced development of genital organs. The University of Florida is in the process of developing oxytocin as an oxytocin receptor agonist for the treatment of PWS. LG Life Sciences Ltd. is in the process of developing eutropin as a somatotropin receptor agonist for the treatment of PWS. Some of the companies and universities having the pipeline of PWS include LG Life Sciences Ltd., University of Florida, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.